Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Tislelizumab for Hepatocellular Carcinoma
NCT06233981Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Median Overall Survival at 24 months. Started Jan 2024; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06233981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233981.